(Q34298935)

English

Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

anti-retroviral agent

0 references

0 references

multiple drug resistance

1 reference

based on heuristic

inferred from title

4-aminosalicylic acid

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

2

object named as

Sherwin K B Sy

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Hartmut Derendorf

8

object named as

Hartmut Derendorf

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Lizanne de Kock

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Bernd Rosenkranz

3

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Andreas H Diacon

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Kim Prescott

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Kenneth R Hernandez

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Mingming Yu

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Peter R Donald

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

language of work or name

0 references

publication date

11 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

58

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

6242-6250

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Cytochrome P450 2B6: function, genetics, and clinical relevance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Timing of antiretroviral therapy for HIV-1 infection and tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

HPLC analysis of para-aminosalicylic acid and its metabolite in plasma, cerebrospinal fluid and brain tissues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Epidemic levels of drug resistant tuberculosis (MDR and XDR-TB) in a high HIV prevalence setting in Khayelitsha, South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Molecular genetics of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Therapeutic drug monitoring in the treatment of tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Pharmacokinetic evaluation of para-aminosalicylic acid granules.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

The early bactericidal activity of drugs in patients with pulmonary tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Bioavailability of Aminosalicylic Acid and Its Various Salts in Humans III: Absorption from Tablets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

6 July 2018

Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Extensively drug-resistant tuberculosis in South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

The absorption, distribution, excretion and fate of para-aminosalicylic acid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Effect of single and of double daily doses of para-aminosalicylic acid in tuberculosis of guinea pigs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

XDR Tuberculosis — Implications for Global Public Health

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4187930

28 October 2018

Isoniazid and para-aminosalicylic acid toxicity in 513 cases: a study including high doses of INH and gastrointestinal intolerance to PAS

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal PAS dosage

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid, and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Once-daily and twice-daily dosing of p-aminosalicylic acid granules

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PREVENTION of streptomycin resistance by combined chemotherapy; a Medical Research Council investigation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ISONIAZID in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; fifth report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical use of a single daily dose of para-aminosalicylic acid in association with isoniazid

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bactericidal Activity of Streptomycin and Isoniazid in Combination with p-Aminosalicylic Acid against Mycobacterium tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of p-aninosalicylic acid and its N-acetylated metabolite in human urine by capillary zone electrophoresis as a measure of in vivo N-acetyltransferase 1 activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25114132

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.03073-14

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34298935&oldid=2143561107"